Lyell Immunopharma (LYEL) Non-Current Assets (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Non-Current Assets data on file, last reported at $83.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 30.92% year-over-year to $83.3 million; the trailing twelve-month figure through Mar 2026 stood at $345.4 million (down 37.8% YoY), and the FY2025 full-year result was $79.1 million, down 28.9% from the prior year.
• Non-Current Assets advanced to $83.3 million in Q1 2026, from $79.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $446.4 million in Q1 2022 to a low of $79.1 million in Q4 2025.
• A 5-year average of $197.3 million and a median of $169.2 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets fell 10.16% in 2022 and tumbled 52.85% in 2025, its largest moves.
• Tracing LYEL's Non-Current Assets over 5 years: stood at $286.3 million in 2022, then plunged by 31.76% to $195.3 million in 2023, then sank by 43.04% to $111.3 million in 2024, then dropped by 28.9% to $79.1 million in 2025, then increased by 5.32% to $83.3 million in 2026.
• Business Quant data shows LYEL's Non-Current Assets at $83.3 million in Q1 2026, $79.1 million in Q4 2025, and $79.8 million in Q3 2025.